Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cryoport; Sales of CAR-T Products Yescarta and Kymriah are In-line with My Projections (CYRX, Buy, $20.67)

Cryoport will report 2Q, 2019 results on August 8, 2019 at 5:00 PM EST. One area of keen interest for investors will be sales relating to the support of the CAR-T products-Gilead’s Yescarta and Novartis’ Kymriah. Gilead has reported that Yescarta sales in 2Q, 2019 were $120 million which compares to my last published estimate of $116 million. Sales of Novartis’ Kymriah were $58 million versus my estimate of $62 million. These results were effectively in-line with my estimates. For more detail on my Cryoport sales and EPS projections for 2Q, 2019 refer to my May 20 report Cryoport: Details of My Model for Sales for 2018 to 2024.

My sales projections for Yescarta and Kymriah are unchanged from the May 20 report and are as follows:


Tagged as , , , + Categorized as LinkedIn, Smith On Stocks Blog


You must be logged in, or you must subscribe to post a comment.